Tirofiban - Merck & Co

Alternative Names: Aggrastat; L 462; L 700462; MK 0383; MK 383; Tirofiban HCl; Tirofiban hydrochloride

Latest Information Update: 23 Nov 2018

Price : $50 ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Merck & Co
Developer 4P Therapeutics; Aspen Pharmacare; Correvio Pharma; Eddingpharm; Medicure
Class Antiplatelets; Aromatic amino acids; Ischaemic heart disorder therapies
Mechanism of Action GPIIb-IIIa antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Marketed Acute coronary syndromes; Arterial thrombosis; Myocardial infarction; Unstable angina pectoris
No development reported Coronary artery restenosis

Most Recent Events

16 Nov 2018 Medicure initiates litigation against Gland Pharma over ANDA submission in the US
24 Jun 2018 Biomarkers information updated
15 May 2018 Tirofiban market-licensed to Cipher Pharmaceuticals in Canada

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight